PCA3 and prostate carcinoma: In their tissue-based cohort, Alshalalfa et al., 2017, also found an association between low PCA3 levels and adverse outcomes, including biochemical recurrence, metastasis, and prostate cancer-specific mortality; however, it is not clear whether such findings are independent of clinical and pathological variables (such as Gleason grade, stage, and group), as a multivariable analysis was not reported.